Brazzein Ice Cream Lowered Blood Sugar Spikes in Liver Disease Trial
Researchers at Russia's Federal Research Centre of Nutrition, Biotechnology and Food Safety reported lower after-meal blood sugar rises after brazzein-sweetened ice cream than after sucrose-sweetened ice cream. The study enrolled 101 adults with metabolic dysfunction-associated steatotic liver disease (MASLD), a condition where excess fat builds up in the liver alongside metabolic problems. Al Jazeera The findings were published in Clinical Nutrition ESPEN.
The design was a randomised trial using ice cream as the test food. Each participant ate a 100-gram serving of vanilla ice cream on three separate test days. The versions were sweetened with sugar, with brazzein, and with brazzein plus inulin, a fermentable fiber. Spikes after the meal were lower after both brazzein versions than after the sugar control. The gap was largest in participants with type 2 diabetes.
Brazzein is a sweet-tasting protein first identified in the West African oubli plant. It is now largely produced through fermentation. Its potency is described at about 2,000 times the sweetness of sugar. ScienceAlert
Prior work has clustered around three questions: taste, toxicology, and whether blood sugar and insulin stay steady. V. Isakov authored a 2026 study on brazzein-sweetened ice cream that reported short-term sensory acceptance comparable to conventional sucrose. MDPI A 2023 article by T. S. Novik presented results of a comprehensive toxicity assessment of yeast-produced recombinant brazzein and monellin. E. V. Markova authored a 2024 article titled 'Sweet protein brazzein as a promising sweetener', in which brazzein is described as an alternative to synthetic sweeteners that does not affect blood sugar and insulin levels. Earlier synthesis includes a 2022 review by M. A. Farag on low-calorie protein and peptide sweeteners including brazzein, pentadin, mabinlin and curculin, and a 2023 article by T. S. Novik titled 'Sweet-Tasting Natural Proteins Brazzein and Monellin'.
The World Health Organization advised in 2023 against the use of non-sugar sweeteners for weight control. That guidance did not settle questions around blood sugar after meals, liver metabolism, or product-specific changes for high-risk groups such as MASLD. Separate research continues elsewhere, including work on carbohydrate-specific blood sugar responses as markers of metabolic subtypes and on immunotherapy reprogramming white blood cells to improve glycemia in type 1 diabetes.
The broader context here is why MASLD and ice cream make a telling test. MASLD concentrates insulin resistance, atherogenic dyslipidemia and excess cardiovascular risk. Ice cream is a tough vehicle because it combines fat, lactose, added sucrose and low-temperature effects that complicate sweetener substitution. Like testing a new engine in a heavy truck, a smaller rise in that setting fits a protein sweetener with little digestible carbohydrate, especially with inulin added. The stronger signal in type 2 diabetes also fits, because MASLD cohorts vary and after-meal control is often weakest where insulin resistance and beta-cell dysfunction occur together.
In my view, acute spikes over hours should be kept separate from chronic outcomes. Lower spikes do not establish improved HbA1c, liver fat, fibrosis progression, body weight, or cardiovascular events. Short-term taste acceptance does not establish adherence, compensation in total energy intake, or gut tolerance with repeated brazzein-inulin use. Toxicology and manufacturing data address a different risk area than long-term metabolic benefit. For clinicians and formulators, the next steps are longer feeding trials with continuous glucose monitoring, grouping by diabetes status and baseline insulin resistance, and head-to-head comparison against other non-nutritive systems under fixed-calorie and free-eating conditions.
